Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol in Greek Patients with Crohn's Disease
NCT00307931Phase 3Terminated
- Sponsor
- UCB
- Start
- Apr 2007
- Primary completion
- Aug 2008
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Primary endpoint: Crohn's Disease Activity Index Decrease of at least 100 points at 6 weeks. Started Apr 2007; status: terminated.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00307931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307931.